SEMA3A and breast ductal adenocarcinoma: Loss of SEMA3A was also associated with higher-grade (grade III) ductal carcinomas and poor survival in a panel of 2878 breast cancer patients [13], associating the loss of SEMA3A with aggressive breast cancer.